Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 8 · newest first

  1. Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II StudyBlood · 2020
  2. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II StudyBlood · 2020
  3. Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Myeloid Leukemia (AML)Blood · 2020
  4. Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First RelapseBlood · 2020
  5. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaJournal of Clinical Oncology · 2020
  6. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutationsCancer · 2020
  7. Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitorsBlood Advances · 2020
  8. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsNature Communications · 2020
  9. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid LeukemiaJAMA Oncology · 2020
  10. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AMLJournal of Hematology & Oncology · 2020
  11. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyBlood · 2020
  12. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosisLeukemia & lymphoma/Leukemia and lymphoma · 2020
  13. Germline DNMT3A mutation in familial acute myeloid leukaemiaEpigenetics · 2020
  14. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutationsAmerican Journal of Hematology · 2020
  15. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicinBritish Journal of Haematology · 2020
  16. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenBlood Cancer Journal · 2020
  17. Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 yearsLeukemia & lymphoma/Leukemia and lymphoma · 2020
  18. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib eraCancer · 2020
  19. Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patientsAmerican Journal of Hematology · 2020
  20. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemiaAmerican Journal of Hematology · 2020
  21. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patientsLeukemia & lymphoma/Leukemia and lymphoma · 2020
  22. Evolutionary Action Score of TP53 Mutations: Integrated Clinico-pathologic And Protein Structural Analysis in Myelodysplastic Syndromes2020
  23. The clinical impact of time to response in de novo accelerated‐phase chronic myeloid leukemiaAmerican Journal of Hematology · 2020
  24. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directionsJournal of Hematology & Oncology · 2020
  25. Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphomaAmerican Journal of Hematology · 2020
  26. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimensHaematologica · 2020
  27. Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALLBlood · 2020
  28. The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor typesCancer · 2020
  29. Treating Leukemia in the Time of COVID-19Acta Haematologica · 2020
  30. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLBlood Advances · 2020
  31. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study databaseLeukemia & lymphoma/Leukemia and lymphoma · 2020
  32. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotypeBlood Cancer Journal · 2020
  33. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaBlood Cancer Journal · 2020
  34. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicinAmerican Journal of Hematology · 2020
  35. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemiaBlood Advances · 2020
  36. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover studyBlood · 2020
  37. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimensBlood Advances · 2020
  38. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoringAmerican Journal of Hematology · 2020
  39. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationHaematologica · 2020
  40. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 StudyClinical Infectious Diseases · 2020
  41. Phase 2 study of hyper‐CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemiaAmerican Journal of Hematology · 2020
  42. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaLeukemia · 2020
  43. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapyAmerican Journal of Hematology · 2020
  44. Clonal Evolution of Acute Myeloid Leukemia Revealed by High-Throughput Single-Cell Genomics2020
  45. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesBlood Advances · 2020
  46. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemiaBlood Advances · 2020
  47. Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemiaCancer · 2020
  48. Long‐term results of frontline dasatinib in chronic myeloid leukemiaCancer · 2020
  49. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AMLBlood · 2020
  50. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factorsBlood · 2020